Validation of SeptiCyte RAPID to discriminate sepsis from non-infectious systemic inflammation

Robert Balk [1], Annette M. Esper [2], Greg S. Martin [2], Russell R. Miller III [3], Bert K. Lopansri [4,5], John P. Burke [4,5], Mitchell Levy [6], Steven Opal [6], Richard E. Rothman [7], Franco R. D'Alessio [7], Venkataramana K. Sidhaye [7], Neil R. Aggarwal[8], Jared A. Greenberg [1], Mark Yoder [1], Gourang Patel [1], Emily Gilbert [9], Jorge P. Parada [9], Majid Afshar [10], Jordan A. Kempker [2], Tom van der Poll [11], Marcus J. Schultz [11], Brendon P. Scicluna [12], Peter M.C. Klein Klouwenberg [13], Janice Liebler [14], Emily Blodget [14], Santhi Kumar [14], Krupa Navalkar [15], Thomas D. Yager [15], Dayle Sampson [15], James T. Kirk [15], Silvia Cermelli [15], Roy F. Davis [15], and Richard B. Brandon [15]

[1]Rush Medical College and Rush University Medical Center, Chicago, Illinois;
[2]Grady Memorial Hospital and Emory University School of Medicine, Atlanta, Georgia;
[3]FirstHealth of the Carolinas, Pinehurst, North Carolina;
[4]Intermountain Medical Center, Murray, Utah;
[5]University of Utah School of Medicine, Salt Lake City, Utah;
[6]Brown University, Providence, Rhode Island;
[7]Johns Hopkins University School of Medicine, Baltimore, Maryland;
[8]Anschutz Medical Campus, University of Colorado, Denver, Colorado;
[9]Loyola University Medical Center, Maywood, Illinois;
[10]University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin;
[11]Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands;
[12]Centre for Molecular Medicine and Biobanking, University of Malta, Malta; and Department of Applied Biomedical Science, Faculty of Health Sciences, Mater Dei hospital, University of Malta, Malta
[13]Isala Hospital, Zwolle, the Netherlands;
[14]Keck Hospital of University of Southern California (USC); and Los Angeles County and USC Medical Center;
[15]Immunexpress Inc., Seattle, Washington

Corresponding Author, to whom requests for reprints and correspondence should be addressed:
Dr. Robert Balk, Rush Medical College and Rush University Medical Center, Chicago, Illinois.

This article has Supplementary Information, which is accessible online and linked to the article.

Running title: Validation of SeptiCyte RAPID for sepsis vs. SIRS

Author Contributions:
Conceptualization: RFD, SC, RBB, DS, TDY
Methodology: RFD, SC, DS, TDY, KN
Investigation: RB, AME, GSM, RRMIII, BKL, JPB, ML, SO, RER, FRDA, VKS, NRA, JAG, MY, GP, EG, MA, FRDA, JPP, JAK, TvdP, MJS, BPS, PMCKK, JL, EB, SK
Supervision: SC, RFD, RB, AME, GSM, RRMIII, BKL,TvdP, JL, EG
Data Curation & Review: SC, DS, KN
Clinical Assessment: SO, RER, ML
Custom software: DS, KN
Visualization: DS, KN, TDY
Formal analysis: DS, KN, TDY, SC
Writing: initial & successive drafts: TDY, RBB, RFD
Writing: review and edits: TDY, RBB, RFD, SC, JTK, RB, GM, JAK, BPS, TvdP, PMCKK
Funding acquisition: Immunexpress, Inc.

Sources of Support: This study was supported by Immunexpress Inc.

Best Descriptor: CRITICAL CARE, 4.12 Sepsis/Multiple Organ Failure

Abstract

Background: SeptiCyte RAPID is a molecular test for distinguishing sepsis from non-infectious systemic inflammation. The objective of this study was the clinical validation of SeptiCyte RAPID, based on testing retrospective (banked) and prospectively collected patient samples.

Methods: The cartridge-based SeptiCyte RAPID assay accepts a PAXgene blood RNA sample and provides sample-to-answer processing in about 1 hour. The test output (SeptiScore, range 0-15) falls into four interpretation bands, with higher scores indicating higher probabilities of sepsis. Retrospective (banked) and prospective samples from adult patients in ICU either having systemic inflammatory response syndrome (SIRS), or suspected of sepsis under either the Sepsis-2 or Sepsis-3 definition were tested, and results were compared to a gold standard of clinical evaluation by a blinded, three-physician external panel. A multivariable analysis was performed, in which SeptiScore was combined with other clinical variables.

Results: With adjudication under the Sepsis-2 definition, SeptiCyte RAPID performance for the complete cohort (356 retrospective + 63 prospective patients) had Area Under the ROC Curve (AUC) ranging from 0.82-0.85, negative predictive value 0.91 (sensitivity 0.94) for SeptiScores between 0.1 and 5.0 (Band 1, lowest risk of sepsis), and positive predictive value 0.81 (specificity 0.90) for SeptiScores between 7.4 and 15 (Band 4, highest risk of sepsis). Performance estimates for the prospective cohort ranged from AUC 0.86-0.95. For physician-adjudicated sepsis cases that were blood culture (+) or blood, urine culture (+)(+), 43/48 (90%) of SeptiCyte scores fell in bands 3 or 4. In multivariable analysis with up to 14 additional clinical variables, SeptiScore was the most important variable for sepsis diagnosis. Comparable results were obtained when the data were reanalyzed under the Sepsis-3 definition.

Conclusions: This study validates SeptiCyte RAPID for differentiating patients with sepsis vs. SIRS, on the first day of ICU admission.

Trial Registration: NCT01905033 (MARS), NCT02127502 (VENUS), NCT05469048 (NEPTUNE, retrospectively registered) at clinicaltrials.gov.

Keywords: sepsis, diagnosis, host response, SIRS, sepsis scoring systems

Background

Sepsis is an important and expensive global health problem with high morbidity and mortality [1]. According to the World Health Organization, more than 11 million people die from sepsis worldwide annually, comprising more than the deaths caused by all cancers combined [2]. Sepsis is the leading cause of death in U.S. hospitals is ranked as the most expensive disease state to manage for admitted patients [3], with total annual costs of treatment and rehabilitation estimated at $62 billion [4]. Before the COVID-19 pandemic, at least 1.7 million adults in the United States developed sepsis annually [5]. During the pandemic, this problem was greatly exacerbated, as most COVID-19 deaths are due to viral and/or bacterial sepsis [6]. Up to 20% of all deaths worldwide can be attributed to sepsis on an annual basis [1].

   Early identification of sepsis and implementation of treatment bundles have been shown to improve outcomes for sepsis patients [7]. However, early identification of sepsis can be difficult for many reasons. In the early stages of the disease, patients present with clinical signs that are common to many other non-infectious conditions [8]. Furthermore, sepsis does not have a diagnostic gold standard since blood cultures lack timeliness [9] and are negative in 30-50% of retrospectively diagnosed cases [10,11]. In addition, unnecessary administration of broad-

spectrum antibiotic therapy for presumed sepsis may adversely contribute to the growing problem of multidrug resistant organisms and carries the risk of adverse drug reactions [12].

We previously reported on the development and validation of a diagnostic assay (SeptiCyte LAB) to differentiate patients with Sepsis-2 from those with non-infectious systemic inflammation, providing a probability of sepsis based on measurement of four host immune response biomarkers [13, 14]. Here we describe SeptiCyte RAPID, a simplified and improved cartridge-based version of this assay. The specific aim of the present work is to provide clinical validation data demonstrating robust performance of SeptiCyte RAPID for discriminating between sepsis and the non-infectious systemic inflammatory response syndrome (SIRS) in a combined cohort of 419 patients on their first day of ICU admission. SeptiCyte RAPID assay addresses a clinical need for more rapid and accurate differentiation of sepsis from SIRS within a clinically actionable (~1 hour) time frame. Some of these results have been presented earlier in the form of an abstract [15].

Methods

SeptiCyte RAPID test description

SeptiCyte RAPID is an *in-vitro* diagnostic test for simultaneous amplification and detection of two RNA transcripts (PLA2G7 and PLAC8) in human blood samples. The test is run on a near-to-patient platform, Idylla, manufactured by Biocartis NV (Mechelen, Belgium). The SeptiCyte RAPID test is performed by pipetting 0.9 mL of PAXgene-stabilized blood (corresponding to 0.24 mL of drawn blood) into a custom cartridge which performs all assay steps including sample extraction/purification and RT-qPCR for the detection and relative quantification of the

PLAC8 and PLA2G7 mRNA targets. Test results are presented automatically through a software-generated report which includes a quantitative sepsis probability score (SeptiScore, range 0-15), calculated by combining the RT-qPCR Cq values measured for PLAC8 and PLA2G7. The test has a hands-on time of ~2 min and a turnaround time of ~1 hour.

Study cohorts

Clinical validation of SeptiCyte RAPID for the discrimination of sepsis from SIRS according to the Sepsis-2 definition used PAXgene blood RNA samples from retrospective (N=356) and prospective (N=63) patient cohorts. The retrospective cohort was drawn from the observational MARS, VENUS and VENUS Supplement trials (www.clinicaltrials.gov NCT01905033 and NCT02127502) which have been previously described [14]. The retrospective cohort comprised 80% of the 447 patients used for the 510(k) clearance of SeptiCyte LAB for which duplicate banked PAXgene blood RNA samples remained available. The recruitment dates were Jan 2011 - Dec 2013 (MARS), May 2014 - Apr 2015 (VENUS) and Mar - Aug 2016 (VENUS Supplement).

The prospective cohort consisted of 63 critically ill adult subjects enrolled in an observational trial (NEPTUNE, www.clinicaltrials.gov NCT05469048) between the dates May 26, 2020 - April 25, 2021 at Emory University / Grady Memorial Hospital (Atlanta GA), Rush University Medical Center (Chicago IL) and University of Southern California Medical Center (with two separate sites, Keck Hospital of USC, and LAC+USC Medical Center, in Los Angeles CA). The study protocol was approved by each institutional review board (see below). All patients (or legally authorized representatives) provided signed informed consent.

By design, the NEPTUNE inclusion/exclusion criteria matched the criteria used earlier in the MARS, VENUS, and VENUS Supplement studies. Subjects were considered for inclusion in NEPTUNE if adult (≥18 years old), exhibited two or more SIRS criteria, and received an ICU admission order. Subjects were operationally defined as "suspected of sepsis" if microbiological tests were ordered within 24 hours of the ICU admission order. Subjects were excluded if therapeutic intravenous antibiotic treatment was initiated >24 hours before ICU admission order, as this would decrease blood culture positivity [16, 17], thus potentially confounding the retrospective physician diagnosis (RPD) process. Extensive early antibiotic treatment could also potentially affect the host response to infection, and thus potentially biasing our SeptiCyte RAPID test scores. As much as possible, enrolments were consecutive; however, during the COVID-19 pandemic, screening did not happen every day, and initial consenting sometimes resulted in later refusal to participate. PAXgene blood samples were collected within 24 hours of ICU admission order, and run fresh, in real time on Idylla instruments installed at the sites. Clinical data were collected on case report forms as described previously [14].

Ethics approvals for the MARS and VENUS trials (retrospective cohort) were previously referenced [14]. Ethics approvals for the NEPTUNE trial (prospective cohort) are as follows: # IRB00115400 (Emory University); # 00-115400 (Grady Memorial Hospital); # 19101603-IRB01 (Rush University Medical Center), and # HS-19-0884-CR001 (University of Southern California Medical Center). A flow diagram describing the origin of all samples used in the study is provided in the Supplementary Information, Section 1.

Reference diagnosis (comparator)

Clinical performance of SeptiCyte RAPID was evaluated by comparison to a 'gold standard' of clinical adjudication. The adjudication process, termed retrospective physician diagnosis (RPD), consisted of clinical evaluations by an external three-member panel of experienced physicians not involved in the care of the patients. For each patient, a chart review was conducted independently by each panel member, leading to a three-way classification (sepsis, SIRS or indeterminate) in accordance with the Sepsis-2 definition (where sepsis is defined as ≥ 2 SIRS + infection) [18]. The vote tally for each patient was either unanimous, consensus (2 of 3), or indeterminate. There were 41/419 (9.8%) indeterminates, which were then reanalyzed and forced into either sepsis or SIRS categories by a second RPD. The Sepsis-2 definition was used because the majority of patients were recruited before the Sepsis-3 definition became available, and because the RAPID SeptiScore does not correlate strongly with organ dysfunction. However, an additional analysis under the Sepsis-3 definition was also conducted. Details are provided below, in reference [14], and in the Supplementary Information, Section 2.

Statistical calculations

Sepsis probability as a function of SeptiScore was calculated by a "sliding window" approach [19]. Briefly, a custom R script was written to conduct a sliding window calculation of the sepsis probability (P) across the 0-15 SeptiScore range. The sliding window was 4 score units wide and was shifted in 1-unit increments from the lower to the upper limit of the SeptiScore range. In each 4-unit wide window, the numbers of sepsis calls (N_{sepsis}) and SIRS calls (N_{SIRS}) were tabulated according to each RPD method, and $P = (N_{sepsis}) / (N_{sepsis} + N_{SIRS})$ was computed for that window. The process was repeated stepwise over the entire 0-15 SeptiScore range.

Sepsis probability as a function of SeptiScore was parsed into four bands, with higher

SeptiScores representing higher probabilities of sepsis. Band boundaries were pre-defined, based

on an independent set of 195 clinical samples from the MARS consortium, to give 90%

sensitivity for binarization at the Band 1/2 cutoff (SeptiScore 4.95) and 80% specificity for

binarization at the Band 3/4 cutoff (SeptiScore 7.45), using site clinical adjudications as Ground

Truth values. The intermediate zone between the Band 1/2 and Band 3/4 cutoffs was divided in

half to define the Band 2/3 cutoff (SeptiScore 6.15).

Receiver-Operating Characteristic (ROC) curve analysis was performed in accordance with

Clinical and Laboratory Standards Institute EP24-A2 using the pROC package [20]. Other

clinical performance measures (clinical sensitivity, clinical specificity, sepsis and SIRS

probabilities, and likelihood ratios) were also calculated. Additional statistical methods for data

analyses, including methods for imputation of missing data and for combining the SeptiScore

with other clinical variables, are described in the Supplementary Information, Sections 3-5.

Results

The SeptiCyte RAPID test

SeptiCyte RAPID measures the relative expression levels of two immune-related mRNAs,

PLAC8 (Placenta-associated 8) and PLA2G7 (Phospholipase A2 Group 7). This expression

signature was discovered using a purely bioinformatic approach when comparing SIRS patients

retrospectively determined to have an infection or not, as described previously [13]. With respect

to biological roles in the host immune response to infection, PLAC8 is reportedly an interferon

inducible gene expressed in a variety of tissues rich in immune cells (e.g. whole blood, spleen, lymph node, colon), and up-regulated in sepsis across a broad range of different peripheral blood cell types including plasmacytoid dendritic and natural killer cells. Additionally, PLA2G7 encodes the protein platelet-activating factor (PAF) acetylhydrolase, a secreted enzyme primarily produced by macrophages that catalyzes the degradation of PAF and hydrolyses the oxidized short chain phospholipids of low-density lipoproteins (LDL), thereby releasing pro-inflammatory mediators (lysophospholipids and oxidized fatty acids). Further discussion and literature references are provided in the Supplementary Information, Section 6.

Demographic and clinical characteristics

Clinical validation of SeptiCyte RAPID was based on testing samples from retrospective (n=356) and prospective (n=63) patient cohorts. Demographic characteristics of the study population are presented in **Table 1**. The majority of patients were recruited over the dates Jan 2011 - Dec 2013 (MARS), May 2014 - Apr 2015 (VENUS) and Mar - Aug 2016 (VENUS Supplement), which largely predate the Sepsis-3 definition [21]. Sepsis, SIRS or indeterminate diagnoses were assigned by RPD under the Sepsis-2 definition, although reanalysis under Sepsis-3 was also done (see below and Supplementary Information, Section 2). When compared to patients with SIRS, patients adjudicated as septic tended to be older (p = 0.016). There were no significant differences by sex or race/ethnicity. Patients originated from a variety of locations within the hospital systems in the study. Patients coming from hospital wards exhibited a higher proportion of sepsis relative to patients coming from the ED (p = 0.0026), post-anesthesia unit / post-operating room (p < 0.00001), or ICU / cardiac care unit (p = 0.024).

Clinical characteristics of the study population are presented in **Table 2.** Of particular note are culture results of high statistical significance: positive blood cultures, positive urine cultures, and dual-positive cultures (blood+urine) were very highly associated with RPD diagnoses of sepsis, as opposed to SIRS, with p-values of 2.7 x 10^{-12}, 3.1 x 10^{-6}, and 9.0 x 10^{-4} respectively. A breakdown of the culture-confirmed pathogens for the sepsis cases is presented in the Supplementary Information, Sections 7-8.

SeptiCyte RAPID performance: primary analyses under Sepsis-2

ROC curve analyses: Receiver operating characteristic (ROC) curve analyses were performed on samples from the retrospective cohort (**Figure 1A**), the prospective cohort (**Figure 1B**), and the combined retrospective + prospective cohorts (**Figure 1C**). Performance estimates for the retrospective cohort ranged from AUC 0.82-0.85 (depending upon RPD method) and were statistically indistinguishable both from each other, and from SeptiCyte LAB AUC values [14]. Performance estimates for the prospective cohort ranged from AUC 0.86-0.95 (depending upon RPD method) and again were statistically indistinguishable from each other.

A statistical comparison of the ROC curves from Figure 1A (retrospective cohort) vs. 1B (prospective cohort) showed an absence of significant differences, except for the unanimous RPD curves in the two figures, for which deLong's test [22] gave p = 0.013. For a binary discrimination of sepsis versus SIRS in the combined retrospective + prospective dataset, using consensus RPD as comparator, the relationship between threshold, sensitivity, and specificity (derived from the appropriate ROC curve) is shown in **Figure 1D**.

Sepsis probability distributions: The distribution of SeptiScores for septic patients falls above that for patients with SIRS (**Figure 2A**). A sliding window analysis (**Figure 2B**) is used to calculate the probability of sepsis as a function of SeptiScore (**Figure 2C**). Patients with higher SeptiScores have higher probabilities of sepsis. The band boundaries were pre-set at 4.95, 6.15 and 7.45 (see Methods section above), giving high sensitivity for Band 1 and high specificity for Band 4. A strong correlation was found between the banding schemes for SeptiCyte RAPID (**Figure 3**) and SeptiCyte LAB [14]. This holds true regardless of whether the retrospective, prospective, or combined cohorts are examined for SeptiCyte RAPID. **Table 3** presents SeptiScores for the complete (retrospective + prospective) cohort, for the retrospective and prospective cohorts separately, and also for SeptiCyte LAB, parsed into the four probability bands. Assignment of sepsis, SIRS or indeterminate was by consensus RPD. The probability of and likelihood ratio for sepsis both increase with increasing SeptiScore. Chi-squared analyses (**Table 4**) indicated that, after sorting patients into the four SeptiScore bands, no significant differences were found with respect to baseline demographic criteria (sex, age, race or ethnicity).

Comparison to culture results: Analysis of data from Tables 2 and 4 indicates that blood+, urine+, and blood+/urine+ (double-positive) culture results were more predominant in the higher SeptiScore bands (especially Band 4). Of the positive results from blood, urine, and blood/urine culture, the percentages falling in Band 4 were 63%, 52% and 73% respectively, and the percentages falling in either Band 3 or Band 4 were 83%, 64% and 82% respectively. Chi-squared analyses gave p-values of 7.2×10^{-6}, 0.023 and 0.005 for the observed distributions of these positive culture results in Band 4 vs. pooled Bands 1+2+3. Of the 48 patients that were called septic by RPD with blood+ or blood+/urine+ culture results, 9/48 (19%) of SeptiScores

fell in band 3 and 34/48 (90%) of SeptiScores fell in band 4. Of the 42 patients with blood+ culture results, only one had a SeptiScore in Band 1. This patient was diagnosed as SIRS by RPD, with the blood culture result being considered a probable contaminant by the attending physician and the RPD panelists.

SeptiCyte RAPID performance: Multivariable analysis

We asked whether SeptiCyte RAPID could provide diagnostic clinical utility for discriminating between sepsis and SIRS patients, beyond that provided by other clinical variables and laboratory assessments available on the first day of ICU admission. Fourteen variables in addition to SeptiCyte RAPID were examined (see Supplementary Information, Sections 9-10). We evaluated all 32,767 possible combinations of the fifteen variables, and performance was assessed by AUC against consensus RPD. Procalcitonin was included in this analysis, as well as lactate which is a commonly used and rapidly assessed variable to determine which patients should receive sepsis treatment bundles [23, 24]. **Figure 4A** shows the results of the multivariable analysis for the combined retrospective and prospective cohorts, while **Figure 4B** shows the comparable results for just the prospective cohort. The AUC distributions for the prospective cohort appear somewhat high compared to those for the full patient cohort, possibly because of overfitting (the prospective cohort has only 54 patients with SIRS or sepsis by consensus RPD, as compared to 154 in the full patient cohort). With respect to individual variables, SeptiScore was found to rank highest by AUC. When combinations of clinical variables were considered, those containing SeptiScore were found to have higher AUCs than all combinations lacking SeptiScore.

SeptiCyte RAPID performance, under the Sepsis-3 framework

In 2016, Singer et al. [21] proposed that the Sepsis-2 definition be replaced with Sepsis-3 which identifies sepsis as "life-threatening organ dysfunction caused by a dysregulated host response to infection". We investigated whether SeptiCyte RAPID data could be interpreted within a Sepsis-3 framework. Figure 1 of reference [21] provides detail on how the Sepsis-3 definition can be operationalized. It was proposed that patients with organ dysfunction (SOFA scores >2) and with infection, or suspected infection, could be considered to have sepsis. Therefore, the key to transitioning from a Sepsis-2 to Sepsis-3 framework lies in stratifying patients who have organ dysfunction (SOFA scores >2) into infection-positive and infection-negative subgroups.

As measures of organ dysfunction, we considered both the complete SOFA score [25] which had been collected for 290/419 (69.2%) of patients, and also, following Grissom et al. [26] and Lambden et al. [27], a partial SOFA score (pSOFA) in which up to 3 of the 7 SOFA components were missing. The pSOFA could be computed for 372/419 (88.8%) of patients. As a proxy measure of infection, we considered whether the Forced RPD by the expert physician panel led to a diagnosis of sepsis or not. The RPD panel considered ≥2 SIRS criteria + infection = sepsis. As all patients had ≥2 SIRS criteria, it follows by logical deduction that if a patient was called septic by the RPD panel, then the patient must have been considered infected.

Analysis of the data under the Sepsis-3 framework, using either pSOFA or SOFA scores and Forced RPD as a proxy for infection, is shown in Figure 5A,B. pSOFA or SOFA scores >2 are considered an indicator of organ dysfunction. The performance of SeptiCyte RAPID for discriminating infection vs. no infection (i.e. sepsis vs. no sepsis) in high pSOFA or high SOFA

patients (Figures 5A, 5B respectively) was strong (AUC = 0.82). This indicates that SeptiCyte

RAPID performs well within the Sepsis-3 framework. If we instead consider the same

discrimination in low pSOFA patients (i.e. patients without organ dysfunction), we find

comparable performance (AUC = 0.81), as shown in Figure 5C. The same trend appears evident

for patients with low SOFA scores (Figure 5D), although in the latter case the numbers are too

low to achieve statistical significance.

Thus, comparing panels A,B with panels C,D we find that SeptiScore discriminated between

the proxy-defined infection (+) and infection (-) groups independently of the extent of organ

dysfunction as measured by either pSOFA or SOFA score. Additional analyses, concerning the

relative independence of SeptiScore on the extent of organ dysfunction, are presented in

Supplementary Material, Section 9.

Discussion

We have presented data validating the use of SeptiCyte RAPID for differentiating sepsis from

SIRS in critically ill adult patients, within a clinically actionable time frame. Patients in this

study came from the ED, post-anesthesia unit, post-operating rooms and wards, and were tested

in the ICU. For the full (retrospective + prospective) cohort, diagnostic performance

of SeptiCyte RAPID under the Sepsis-2 definition was equivalent to that previously reported for

SeptiCyte LAB [14] with AUC ranging from 0.81 – 0.84 depending upon

comparator method (RPD). Using consensus RPD as reference, patients with Band 1

SeptiScores had an estimated 9% probability of sepsis, while those with Band 4 SeptiScores had

a much higher estimated probability of sepsis (~81%). For the prospective cohort, diagnostic

performance of SeptiCyte RAPID based on AUC was higher than for the full cohort, ranging from 0.86 – 0.98 depending upon RPD method. With consensus RPD, patients with SeptiScores in Band 1 were estimated to have a ~0% average probability of sepsis, while patients with SeptiScores in Band 4 were estimated to have an average sepsis probability of ~83%.

We note that the comparator method (RPD) is imperfect. In the complete (n=419) validation dataset, three expert clinicians failed to reach either a unanimous or consensus diagnosis for 41/419 (9.8%) of patients. The use of an imperfect comparator sets an upper limit to the measurable diagnostic performance of a new test [28]. This observation mirrors the real-life reality that the diagnosis of sepsis is often difficult, even with a retrospective chart review that includes all the clinical data and outcome information.

We investigated whether SeptiCyte RAPID data could be interpreted within a Sepsis-3 framework. As a quantitative measure of organ dysfunction we used the SOFA or pSOFA score [21, 25-27]. As a proxy measure of infection we used forced RPD calls by the expert panel of physicians. The results (Figure 5) indicated that SeptiScore was able to discriminate between the proxy-defined infection (+) and infection (-) groups independently of the extent of organ dysfunction as measured by pSOFA or SOFA score, indicating that SeptiScore has high diagnostic performance for detecting sepsis (AUC 0.81-0.82) under either the the Sepsis-2 or Sepsis-3 framework. As SeptiCyte RAPID performance appears independent of organ dysfunction, we hypothesize that the SeptiCyte RAPID expression signature may be responding to some process or condition in the septic trajectory occurring earlier than organ damage, likely related to the presence of an infection. A similar hypothesis has been stated by Lukaszewski et al. [29] in connection with an independently discovered sepsis signature.

In a multivariable analysis, we examined all possible combinations of SeptiScore and up to 14 additional clinical or laboratory variables, including lactate and PCT. We found that SeptiScore alone had greater performance than any combination of variables without SeptiScore, for differentiating sepsis vs. SIRS (Figure 4). However, the analysis also indicated it should be possible to moderately boost the performance of SeptiCyte RAPID by combining the SeptiScore with other clinical parameters.

We note several limitations to this study. We have focused only on adult patients within 24 hours of ICU admission, so generalization to other patient cohorts not been established. To avoid potential confounding effects, the study excluded subjects who received therapeutic antibiotic treatment > 24 hours before ICU admission, which could comprise a significant fraction of patients transferred from the floor to ICU. Most of the study was based on re-analysis of banked samples (356/419 = 85%), while only 63/419 (15%) were prospectively collected. We have not conducted serial sampling to measure variation in SeptiCyte RAPID scores as patients move into, through, and out of, ICU. We have, however, previously reported strong diagnostic performance of SeptiCyte LAB in children [30], and the high correlation between SeptiCyte LAB and SeptiCyte RAPID suggests that an equivalently strong performance in children will be found for SeptiCyte RAPID.

SeptiScores falling in Bands 2 or 3 do not, by themselves, provide definitive conclusions (i.e. very high or low probabilities) regarding the absence or presence of sepsis. For SeptiScores in this range, interpretation would be enhanced by combining the readings with data from other clinical variables, to adjust the post-test sepsis probabilities (see Figure 4).

During the discovery and initial validation of the PLAC8 and PLA2G7 biomarkers [13, 14], patients with a broad range of co-morbidities were examined, including septic patients with confirmed bacterial, viral, fungal infections and malignancies, and non-septic patients with non-infectious systemic inflammation of varying etiologies. The validation cohort also included use of a broad range of prescribed medications such as immunosuppressants, anti-neoplastic drugs, antithrombotics, corticosteroids and statins. To our knowledge, SeptiCyte RAPID results are unaffected by these factors, as reported in a previous preliminary analysis [31]. However, there may be other specific conditions and treatments we have not yet examined, that could affect SeptiCyte RAPID performance.

Although the dynamic range of SeptiCyte RAPID is broad and extends well below and above the 4,000-11,000 WBC/uL normal reference range, we have not yet completed an evaluation of the assay on severely neutropenic patients, although in a previous preliminary analysis we reported that SeptiCyte performance was maintained in patients treated with anti-neoplastic drugs [31]. It is possible that SeptiCyte RAPID scores might be skewed by selective leukopenias due to disease or medications, for example T cell depletion in HIV / AIDS. However, it is known from single cell sequencing studies that both PLAC8 and PLA2G7 are expressed across a range of different white cell types [32] which would mitigate the effect of a selective leukopenia.

The recently updated Surviving Sepsis Campaign (SSC) guidelines (2021) divide patients into three groups (low, intermediate, and high) based on sepsis probability, and recommend appropriate evaluation and treatment of these groups [33]. SeptiCyte RAPID aligns well with these guidelines and could have a role in supporting their implementation.

The SSC 'low sepsis probability' group has, under previous guidelines, been treated early resulting in poor antibiotic stewardship. The new guidelines recommend deferring antibiotics, and monitoring and evaluate for other etiologies that may underlie the presenting symptoms. A SeptiScore <5 (Band 1) with a sensitivity of 0.94 in this group of patients could potentially support the deferring of antibiotics, at least until clinical microbiology results became available, thereby facilitating antibiotic and diagnostic stewardship.

For patients falling in the SSC 'intermediate sepsis probability (without shock)' group, the SSC recommendation is a rapid assessment of infectious versus non-infectious cause of the illness. Septicyte RAPID, with a one-hour turnaround time, rapidly differentiates infectious positive from infection negative systemic inflammation. The presence of elevated SeptiScores (Band 3 or Band 4) in this group would provide supporting evidence for infectious etiology, and for early antibiotic administration 24 to 48 hours before any positive microbiological results are available. The resulting SeptiScore turnaround time of ~1 hour would also aid in meeting the recommended 3-hour initiation of antibiotics for this group.

Per the SSC guidelines, those patients in the 'high sepsis probability' group, differentiated by the presence of shock, should appropriately be treated within 1 hour of recognition. SeptiScores in Band 4 (>7.5) in this patient group, with specificity 0.9 or greater, would provide evidence for a high probability of sepsis and the continuation of antibiotics.

Although SeptiCyte RAPID provides a fast turnaround time (~1 hour) between pipetting a blood sample into the SeptiCyte RAPID cartridge and generating a test report, by the time patient blood is drawn and delivered e.g. to a STAT lab, the total time between blood draw and presentation of the test result to an attending clinician is likely to be 1.5-2 hours. Although this is

longer than requirements to implement a 1-hour sepsis bundle, SeptiCyte RAPID would provide timely information with respect to implementing a 3-hour sepsis bundle, which has been shown to have a low level of compliance in US hospitals [34, 35]. Compliance with a 3-hour sepsis bundle in patients with severe sepsis and septic shock has been shown to improve survival and reduce overall costs [35].

Conclusions

This study validates SeptiCyte RAPID for differentiating patients with sepsis vs. SIRS, on the first day of ICU admission. With a turnaround time of ~1 hour, SeptiCyte RAPID provides actionable test results within a clinically relevant timeframe. SeptiCyte RAPID may thus provide clinical utility through helping to guide patient management decisions on the implementation and timing of sepsis bundles.

Supplementary information

Supplementary information accompanies this paper.

Abbreviations

%A, Percent Agreement; ANOVA, Analysis of Variance; AUC, Area Under (Receiver Operator Characteristic) Curve; CAD, Coronary artery disease; CKD, Chronic kidney disease; CPAP, Continuous positive airway pressure; Cq, Quantification Cycle (for PCR); CRP, C-Reactive Protein; ED, Emergency Department; ICU, Intensive Care Unit; IQR, Interquartile Range; Ku, Unweighted inter-observer kappa; Kw, Linearly weighted inter-observer kappa; LR, Likelihood Ratio; PCR, Polymerase Chain Reaction; PCT, Procalcitonin; PLA2G7, Phospholipase A2,

Group VII; PLAC8, Placenta associated 8; ROC, Receiver Operator Characteristic (curve); RPD, Retrospective Physician Diagnosis; RT-qPCR, Reverse Transcription - Quantitative Polymerase Chain Reaction; SIRS, Systemic Inflammatory Response Syndrome; SSC, Surviving Sepsis Campaign; Tukey HSD, Tukey Honestly Significant Difference; WBC, White Blood Cell.

Declarations

Ethics approval and consent to participate

Ethics approvals for the MARS and VENUS trials (retrospective cohort) were previously referenced (Miller et al., Am J Resp Crit Care Med. 2018;198:903-13). Ethics approvals for the NEPTUNE trial (prospective cohort) are as follows: # IRB00115400 (Emory University); # 00-115400 (Grady Memorial Hospital); # 19101603-IRB01 (Rush University Medical Center), and # HS-19-0884-CR001 (University of Southern California Medical Center). All subjects, or their legally authorized representatives, gave consent for participation in this study.

Consent for publication

Not applicable, as this manuscript does not contain data from any individual person.

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

Competing interests

KN, TDY, DS, JTK, SC, RFD and RBB declare they are present or past employees or shareholders of Immunexpress, Inc. No other competing interests are declared.

Funding

This work was funded by Immunexpress, Inc.

Authors' contributions

Conceptualization: RFD, SC, RBB, DS, TDY

Methodology: RFD, SC, DS, TDY, KN

Investigation: RB, AME, GSM, RRMIII, BKL, JPB, ML, SO, RER, FRDA, VKS, NRA, JAG, MY, GP, EG, MA, FRDA, JPP, JAK, TvdP, MJS, BPS, PMCKK, JL, EB, SK

Supervision: SC, RFD, RB, AME, GSM, RRMIII, BKL,TvdP, JL, EG

Data Curation & Review: SC, DS, KN

Clinical Assessment: SO, RER, ML

Custom software: DS, KN

Visualization: DS, KN, TDY

Formal analysis: DS, KN, TDY, SC

Writing: initial & successive drafts: TDY, RBB, RFD

Writing: review and edits: TDY, RBB, RFD, SC, JTK, RB, GM, JAK, BPS, TvdP, PMCKK

Funding acquisition: Immunexpress, Inc.

Acknowledgements

The authors thank the clinical study coordinators of the NEPTUNE study: Joyce D. Brown (Rush University), Liliacna Jara (University of Southern California), Leona Wells and Maya C. Whaley (Grady Memorial Hospital). The authors also thank the laboratory technical staff at each institution,at Reach Bio (Seattle WA), and at Biocartis (Mechelen, Belgium).

References

1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–11.

2. Kempker JA, Martin GS. A global accounting of sepsis. Lancet. 2020;395:168-70.

3. Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Statistical Brief #204, published May, 2016. Rockville (MD): Agency for Healthcare Research and Quality (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK368492/

4. Paoli, C. J., Reynolds, M. A., Sinha, M., Gitlin, M. & Crouser, E. Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level. Crit Care Med. 2018;46:1889–97.

5. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al.; CDC Prevention Epicenter Program. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. JAMA. 2017;318:1241-9.

6. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11:4263.

7. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018; 44:925-8.

Balk R et al. Validation of SeptiCyte RAPID for sepsis vs. SIRS

8. Liu VX, Bhimarao M, Greene JD, Manickam RN, Martinez A, Schuler A, et al. The Presentation, Pace, and Profile of Infection and Sepsis Patients Hospitalized Through the Emergency Department: An Exploratory Analysis. Critical Care Explor. 2021;3:e0344.

9. Lambregts, M. M. C., Bernards, A. T., Beek, M. T. van der, Visser, L. G. & Boer, M. G. de. Time to positivity of blood cultures supports early re-evaluation of empiric broad-spectrum antimicrobial therapy. PLOS One. 2019;14:e0208819.

10. Panday, RSN, Lammers, E. M. J., Alam, N. & Nanayakkara, P. W. B. An overview of positive cultures and clinical outcomes in septic patients: a sub-analysis of the Prehospital Antibiotics Against Sepsis (PHANTASi) trial. Crit Care. 2019;23:182

11. Panday RSN, Wang S, Ven PM van de, Hekker TAM, Alam N, Nanayakkara PWB. Evaluation of blood culture epidemiology and efficiency in a large European teaching hospital. PLOS One. 2019;14:e0214052.

12. Kadri, SS. Key takeaways from the U.S. CDC's 2019 antibiotic resistance threats report for frontline providers. Crit Care Med. 2020;48:939-45.

13. McHugh L, Seldon TA, Brandon RA, Kirk JT, Rapisarda A, Sutherland AJ, et al. A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts. PLOS Med. 2015;12:e1001916.

Balk R et al. Validation of SeptiCyte RAPID for sepsis vs. SIRS

14. Miller RR 3rd, Lopansri BK, Burke JP, Levy M, Opal S, Rothman RE, et al. Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. Am J Resp Crit Care Med. 2018;198:903-13.

15. Kirk J, Yager T, Cermelli S, Sampson D, Brandon R, Sillekens P, et al. Clinical performance of a rapid sepsis test on a near-patient molecular testing platform. Abstract # P481, ISICEM 2020, Brussels, Belgium.

16. Rand KH, Beal SG, Rivera K, Allen B, Payton T, Lipori GP. Hourly Effect of Pretreatment With IV Antibiotics on Blood Culture Positivity Rate in Emergency Department Patients. Open Forum Infect Dis. 2019;6:ofz179.

17. Scheer CS, Fuchs C, Gründling M, Vollmer M, Bast J, Bohnert JA, et al. Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a prospective clinical cohort study. Clin Microbiol Infect. 2019;25:326-331.

18. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definition conference. Crit Care Med. 2003;31:1250–6.

19. Arasu A & Manku GS. Approximate Counts and Quantiles over Sliding Windows. PODS 2004: Proceedings of the twenty-third ACM SIGMOD-SIGACT-SIGART symposium on principles of database systems, June 14-16, 2004. Pages 286–296. DOI: 10.1145/1055558.1055598.

20. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77-84.

21. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-810.

22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.

23. Faust JS, Weingart SD. The Past, Present, and Future of the Centers for Medicare and Medicaid Services Quality Measure SEP-1: The Early Management Bundle for Severe Sepsis/Septic Shock. Emerg Med Clin North Am. 2017;35:219-31.

24. Rhee C, Chiotos K, Cosgrove SE, Heil EL, Kadri SS, Kalil AC, et al. Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. Clin Infect Dis. 2020;72:ciaa059.

25. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):762-774. Erratum in: JAMA. 2016;315:2237.

26. Grissom CK, Brown SM, Kuttler KG, Boltax JP, Jones J, Jephson AR, Orme JF Jr. A modified sequential organ failure assessment score for critical care triage. Disaster Med Public Health Prep. 2010;4:277-284.

27. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019;23:374-382.

28. Lopansri BK, Miller RR III, Burke JP, Levy M, Opal S, Rothman RE, et al. Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohort. J Intensive Care. 2019;7:13.

29. Lukaszewski RA, Jones HE, Gersuk VH, Russell P, Simpson A, Brealey D, et al. Presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures. Intens Care Med. 2022;48:1133-1143.

30. Zimmerman JJ, Sullivan E, Yager TD, Cheng C, Permut L, Cermelli S, et al. Diagnostic Accuracy of a Host Gene Expression Signature That Discriminates Clinical Severe Sepsis Syndrome and Infection-Negative Systemic Inflammation Among Critically Ill Children. Crit Care Med. 2017;45:e418–e425.

31. Davis R, Navalkar K, van der Poll T, Schultz M, Zimmerman J, Cremer O, Bonton M. SeptiCyte RAPID in Sepsis Cases With Malignancy or Treated With Antineoplastics/Immunosuppressants. Critical Care Medicine 2021;49:643. DOI: 10.1097/01.ccm.0000730988.05701.eb

32. Reyes M, Filbin MR, Bhattacharyya RP, Billman K, Eisenhaure T, Hung DT, et al. An immune-cell signature of bacterial sepsis. Nat Med. 2020;26:333–40.

33. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49:e1063-e1143.

34. Deis, A. S., Whiles, B. B., Brown, A. R., Satterwhite, C. L. & Simpson, S. Q. Three-Hour Bundle Compliance and Outcomes in Patients With Undiagnosed Severe Sepsis. Chest. 2018;153:39–45.

35. Leisman DE, Doerfler ME, Ward MF, Masick KD, Wie BJ, Gribben JL, et al. Survival Benefit and Cost Savings From Compliance With a Simplified 3-Hour Sepsis Bundle in a Series of Prospective, Multisite, Observational Cohorts. Crit Care Med. 2017;45:395-406.

FIGURE LEGENDS

Figure 1. Diagnostic performance of SeptiCyte RAPID. ROC curve analyses for SeptiCyte RAPID were performed using three different RPD methods (consensus, forced and unanimous), for either the full cohort (retrospective and prospective patients) or the prospective cohort. DeLong's test [22] was used to determine if differences between curves were statistically significant. **(A)** Full cohort ROC curves for forced (black), consensus (blue) and unanimous (red) RPD, with AUC = 0.82, 0.85 and 0.85 respectively. **(B)** Prospective cohort ROC curves for

forced (black), consensus (blue) and unanimous (red) RPD, with AUC = 0.86, 0.90 and 0.95 respectively.

Figure 2. Probability of sepsis as a function of SeptiScore. **(A)** Cumulative distributions of the SeptiScore for SIRS patients (black) and sepsis patients (red), as evaluated by consensus RPD. **(B)** Basis of sliding window calculation of P(sepsis) across the 0-15 SeptiScore range. A sliding window was defined to be 3 score-units wide initially (from 0 to 3), and 2-score-units wide thereafter. It was shifted in 1-unit increments. The number of sepsis and SIRS in each placement of the window was counted, and P(sepsis) calculated as $N_{sepsis} / (N_{sepsis} + N_{SIRS})$. **(C)** Probability of sepsis as function of SeptiScore, from the sliding window analysis. Key: black curve, forced RPD; blue curve, consensus RPD; red curve, unanimous RPD. **(D)** Division of SeptiScore range into four sepsis probability bands.

Figure 3. Comparison of sepsis probabilities per band for **(A)** SeptiCyte RAPID combined retrospective + prospective cohorts (N=378), **(B)** SeptiCyte RAPID retrospective cohort (N=324), and **(C)** SeptiCyte RAPID prospective cohort (N=54). Assignment of sepsis or SIRS was by consensus RPD. Subjects called "indeterminate" by consensus RPD are not included. The ratio to the right of each whisker (x:y) indicates the number of patients called as sepsis (x) or SIRS (y) in the associated SeptiScore band. The number above each whisker describes the percentage of sepsis calls in each band. The error bars represent the lower and upper bounds of the 80% confidence interval for the sample proportion, calculated using the exact binomial formula.

Figure 4. Comparison of lactate, procalcitonin and SeptiScore, without or with additional clinical variables, for discrimination of sepsis vs. SIRS. **(A)** Data from the combined retrospective and prospective cohorts. **(B)** Data from just the prospective cohort. Area under curve (AUC) distributions are shown for all 32,767 possible logistic combinations of the following variables: age, race (African-American or not), sex, MAP max, T min, T max, HR min, HR max, WBC min, WBC max, glucose max, lactate, procalcitonin, SeptiScore, num.SIRS. (Abbreviations: MAP, mean arterial pressure; T, core body temperature; HR, heart rate; WBC, white blood cell count; num.SIRS, number of SIRS criteria met.) Performance was assessed against consensus RPD. Key: grey vertical line, lactate alone; grey distribution, lactate combined with other clinical variables except SeptiScore or PCT; blue vertical line, PCT alone; blue distribution, PCT combined with other clinical variables except SeptiScore; red vertical line, SeptiScore alone; red distribution, SeptiScore combined with other clinical variables.

Figure 5. SeptiScore performance stratified by SOFA score and infection status. (A) Patients with organ dysfunction (partial SOFA ≥2), stratified into infection (+) (black) and infection (-) (red) groups. Forced RPD is the proxy for infection. (B) Patients with organ dysfunction (complete SOFA ≥2), stratified into infection (+) (black) and infection (-) (red) groups. Forced RPD is the proxy for infection. (C) Patients without organ dysfunction (partial SOFA <2), stratified into infection (+) (black) and infection (-) (red) groups. Forced RPD is the proxy for infection. (D) Patients without organ dysfunction (complete SOFA <2), stratified into infection (+) (black) and infection (-) (red) groups. The SOFA components [25] are PaO2/FiO2 ratio, Glasgow coma score, mean arterial pressure, administration of vasopressors, serum creatinine, bilirubin, platelet count. Complete SOFA was calculated across a subset of 372/419 (88.8%) of patients for whom all SOFA components had been recorded. Partial SOFA [26, 27] was

calculated across a subset of 290/419 (69.2%) of patients in which 267, 71, 21, 9 patients were

missing 0, 1, 2, or 3 SOFA components respectively.

Table 1. Demographic characteristics of study population. There were 41 (9.8%) indeterminates by consensus RPD, which are not shown in this table or included in the p-value calculations. Student's t-test was used to calculate p-values for the indicated comparisons.

Parameter		SIRS (N=224) (Consensus)	Sepsis (N=154) (Consensus)	p-value
		N (%)	N (%)	
Age	Median (Interquartile range, IQR))	57 (42-69)	62 (49-71)	p = 0.016
Sex	Female	98 (58%)	71 (42%)	female vs. male p = 0.65
	Male	126 (60%)	83 (40%)	
Race / Ethnicity	Asian	10 (53%)	9 (47%)	white vs. non-white[1] p = 0.75 white vs. black p = 0.39
	Black (American or European of African descent)	65 (64%)	37 (36%)	
	Hispanic	11 (52%)	10 (48%)	
	Other	1 (50%)	1 (50%)	
	Unknown	2 (50%)	2 (50%)	
	White	135 (59%)	95 (41%)	
Study Site	Europe (1 site)	76 (60%)	50 (40%)	Europe vs. USA p = 0.76
	United States (9 sites)	148 (59%)	104 (41%)	
Source of Admission	Emergency department	138 (59%)	95 (41%)	ED vs. ward p = 0.0026 (post-anaesthesia or post-op) vs. ward p < 0.00001 ICU or CCF vs. ward p = 0.024
	Post Anesthesia Unit or Post-Operating Room	34 (83%)	7 (17%)	
	ICU	7 (58%)	5 (42%)	
	ICU, other hospital	14 (54%)	12 (46%)	
	Coronary care facility (CCF)	4 (80%)	1 (20%)	
	Wards	13 (33%)	26 (67%)	
	Other	13 (62%)	8 (38%)	

[1]Hispanic grouped with non-white for this comparison

Table 2. Clinical characteristics of the study population. Consensus RPD was used as the comparator. There were 41/419 (9.8%) indeterminates by consensus RPD, which are not shown in this table or included in the p-value calculations. For categorical variables, the "N-1" chi-squared test was used to calculate p-values for the difference in prevalence (%) of observations of each type across the SIRS and sepsis categories. For continuous variables, Welch's two sample t-test was used to calculate p-values across the SIRS and sepsis categories. Abbreviation: n.a., not appropriate.

Category	SIRS (n=224; 59.3%)	Sepsis (n=154; 40.7%)	p-value
	N (%) or Median (IQR)	N (%) or Median (IQR)	
Culture results			
Blood (+/- Other)	3 (1.34%)	38 (24.7%)	<0.0001
Urine (+/- Other)	2 (0.89%)	21 (13.6%)	<0.0001
Blood + Urine (+/- Other) (double positive)	0 (0%)	10 (6.49%)	0.0001
Sputum (+/- Other)	13 (5.8%)	19 (12.3%)	0.03
Other culture*	19 (8.5%)	20 (13.0%)	0.2
Viral positives / coinfections (by PCR)	9 (4.0%)	16 (10.4%)	0.02
No culture data recorded**	178 (79.5%)	30 (19.5%)	<0.0001
Presumed initial site of infection			
Pulmonary (N=58)	8 (3.6%)	50 (32.5%)	<0.0001
Abdominal (N=28)	1 (0.45%)	27 (17.5%)	<0.0001
Blood (N=16)	0 (0%)	16 (10.4%)	<0.0001
Urinary Tract (N=25)	2 (0.89%)	23 (14.9%)	<0.0001
Central Nervous System (N=9)	4 (1.8%)	5 (3.25%)	0.4
Other (N=16)	2 (0.89%)	14 (9.1%)	0.0001
Multiple (N=5)	0 (0%)	5 (3.25%)	0.007
Not Identified at Initial Evaluation (N=226)	207 (92.4%)	19 (12.3%)	<0.0001
Clinical parameters (Median, IQR)			
Minimum Temperature (°C)	36 (35.5-36.4)	36.1 (35.2-36.7)	0.9
Maximum Temperature (°C)	37.2 (36.9-37.8)	37.8 (37.2-38.6)	< 0.001

Balk R et al. Validation of SeptiCyte RAPID for sepsis vs. SIRS

Category	SIRS (n=224; 59.3%)	Sepsis (n=154; 40.7%)	p-value
	N (%) or Median (IQR)	N (%) or Median (IQR)	
SOFA	6.0 (4.0-8.0)	7.0 (5.0-9.0)	0.004
Procalcitonin (ng/mL)	0.28 (0.05-1.33)	5.19 (0.85-25.72)	<0.0001
WBC max (cells/uL x 10^{-3})	12.65 (8.3-17.20)	14.9 (9.94-21.15)	0.0002
Lactate (mmol/L)	2.05 (1.40-3.27)	2.40 (1.55-4.05)	0.5
Interventions (Median, IQR)			
Invasive mechanical ventilation	86 (38.4%)	52 (33.8%)	0.4
Antibiotic administration	134 (59.8%)	149 (96.8%)	<0.0001
Vasopressor Use	59 (26.3%)	68 (44.2%)	0.003
Outcomes (Median, IQR)			
Hospital length of stay (days)	4 (3-7)	8 (4-15)	< 0.001
ICU length of stay (days)	1.8 (1.2-3.3)	3.2 (1.7-7.0)	< 0.001
Death	19 (8.5%)	22 (14.3%)	0.08
SeptiCyte RAPID Score *** (Median, IQR)	5.3 (4.6-6.3)	7.9 (6.8-9.6)	<0.0001

* Other culture includes the following sample types: bronchial combicath, bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), pus, nares, stool, throat swab, drain fluid, body fluid, interstitial fluid, skin swab. This category also includes one Cryptococcal antigen positive result.

** including 7 positive blood cultures deemed to be false positives

*** Clinicians did not have access to SeptiCyte RAPID Scores during their clinical assessments of patients

Table 3. Interpretation of SeptiCyte RAPID scores. This table provides the performance metrics for SeptiScores falling within each band. The consensus RPD method was used as comparator in all analyses.

SeptiScore Band	Cohort	Average Probability		Sepsis Likelihood Ratio	Percentage of Cohort
		SIRS	Sepsis		
Band 4 (7.4 – 15) High Risk of Sepsis	Retrospective	20 (20%)	81 (80%)	5.89	31%
	Prospective	3 (17%)	15 (83%)	7.27	33%
	Combined	23 (19%)	96 (81%)	6.07	32%
Band 3 (6.2 – 7.3)	Retrospective	34 (58%)	25 (42%)	1.07	18%
	Prospective	7 (58%)	5 (42%)	1.04	22%
	Combined	41 (58%)	30 (42%)	1.06	19%
Band 2 (5.0 – 6.1)	Retrospective	60 (78%)	17 (22%)	0.41	24%
	Prospective	13 (87%)	2 (13%)	0.22	28%
	Combined	73 (79%)	19 (21%)	0.38	24%
Band 1 (0 – 4.9) Low Risk of Sepsis	Retrospective	78 (90%)	9 (10%)	0.17	27%
	Prospective	9 (100%)	0 (0%)	0.00	17%
	Combined	87 (91%)	9 (9%)	0.15	25%

Table 4. Characteristics of all patients stratified by RPD, demographic and clinical parameters, and SeptiScore band. A chi-squared test or ANOVA was used, for categorical variables or continuous variables, respectively, to estimate p-values across or within the SeptiScore bands as appropriate. In the chi-squared analyses, p(Bi, i=1...4) means the probability of the observed vs. expected distributions of patients across sub-categories (e.g. male, female; or Black, White, Other) within band Bi.

Category	Subcategory	SeptiScore 0-4.9 (Band B1) (N=104; 24.8%)	SeptiScore 5-6.1 (Band B2) (N=103; 24.6%)	SeptiScore 6.2-7.3 (Band B3) (N=82; 19.6%)	SeptiScore 7.4-15 (Band B4) (N=130; 31.0%)	Significance
RPD Process						
RPD: Consensus (sepsis+SIRS = 378)	Indeterminate (N=41; 9.8%)	8 (7.7%)	11 (10.7%)	11 (13.4%)	11 (8.5%)	p(B1,B2,B3,B4) = 1.6×10^{-9}, 4.7×10^{-4}, 0.53, $<1.0 \times 10^{-15}$
	Sepsis (N=154; 36.8%)	9 (8.6%)	19 (18.4%)	30 (36.6%)	96 (73.8%)	
	SIRS (N=224; 53.5%)	87 (83.6%)	73 (70.9%)	41 (50.0%)	23 (17.7%)	
RPD: Forced (sepsis+SIRS = 419)	Sepsis (N=176; 42.0%)	13 (12.5%)	23 (22.3%)	37 (45.1%)	103 (79.2%)	p(B1,B2,B3,B4) = 1.1×10^{-9}, 5.2×10^{-5}, 0.57, $<1.0 \times 10^{-15}$
	SIRS (N=243; 58.0%)	91 (87.5%)	80 (77.7%)	45 (54.9%)	27 (20.8%)	
RPD: Unanimous (sepsis+SIRS = 276)	Sepsis (N=119; 28.4%)	7 (6.7%)	12 (11.6%)	23 (28.0%)	77 (59.2%)	p(B1,B2,B3,B4) = 6.3×10^{-7}, 6.0×10^{-4}, 0.97, 3.2×10^{-15}
	SIRS (N=157; 37.5%)	60 (57.7%)	51 (49.5%)	30 (36.6%)	16 (12.3%)	
	N/A (N=143; 34.1%)	37 (35.6%)	40 (38.8%)	29 (35.4%)	37 (28.5%)	
Demographics						
Age	Median, (Q1-Q3)	56.5 (42.8-68.2)	59 (44.5-69)	58 (41.2-74)	62 (48.2-70)	p = 0.59
Sex	female (N=187; 44.6%)	46 (44.2%)	41 (39.8%)	37 (45.1%)	63 (48.5%)	p(B1,B2,B3,B4) = 0.93, 0.33, 0.92, 0.38
	male (N=232; 55.4%)	58 (55.8%)	62 (60.2%)	45 (54.9%)	67 (51.5%)	
Race	Black (N=115; 27.4%)	25 (24.0%)	33 (32.0%)	21 (25.6%)	36 (27.7%)	p(B1,B2,B3,B4) = 0.70, 0.22, 0.20, 0.92
	White (N=254; 60.6%)	65 (62.5%)	63 (61.2%)	46 (56.1%)	80 (61.5%)	
	Other (N=50; 11.9%)	14 (13.5%)	7 (6.8%)	15 (18.3%)	14 (10.8%)	
Culture Results*						
Blood (+/- secondary)	Number (%) positive (out of 42)	1 (2.4%)	7 (16.6%)	8 (19.5%)	26 (63.4%)	p < 0.0001
Urine (+/- secondary)	Number (%) positive (out of 24)	4 (16.6%)	4 (16.6%)	3 (12.5%)	13 (54.2%)	p = 0.1
Blood + Urine (+/- tertiary)	Number (%) double positive (out of 10)	0 (0.0%)	1 (10%)	1 (10%)	8 (80%)	p = 0.009

Balk R et al. Validation of SeptiCyte RAPID for sepsis vs. SIRS

Category	Subcategory	SeptiScore 0-4.9 (Band B1) (N=104; 24.8%)	SeptiScore 5-6.1 (Band B2) (N=103; 24.6%)	SeptiScore 6.2-7.3 (Band B3) (N=82; 19.6%)	SeptiScore 7.4-15 (Band B4) (N=130; 31.0%)	Significance
Sputum (+/- secondary)	Number (%) positive (out of 35)	8 (22.9%)	1 (2.9%)	9 (25.7%)	17 (48.5%)	p = 0.01
Other culture/results**	Number (%) positive (out of 42)	11 (26%)	10 (24%)	8 (19%)	13 (31%)	p = 1.0
Viral acute (by PCR)	Number (%) positive (out of 24)	1 (4%)	3 (12%)	8 (32%)	12 (52%)	p = 0.01
No positive culture or PCR data recorded ***	Number (%) without positive culture or PCR data recorded (out of 242)	79 (32.8%)	77 (32%)	45 (18.7%)	41 (16.5%)	p <0.0001
Presumed Initial Site of Infection*						
Pulmonary	Number (%) out of 74	6 (8%)	11 (15%)	17 (23%)	40 (54%)	p <0.0001
Abdominal	Number (%) out of 34	2 (5.9%)	7 (20.6%)	6 (17.6%)	19 (55.9%)	p = 0.01
Blood	Number (%) out of 17	1 (5.9%)	2 (11.8%)	3 (17.6%)	11 (64.7%)	p = 0.02
Urinary Tract	Number (%) out of 26	3 (11.5%)	5 (19.2%)	2 (7.7%)	16 (61.5%)	p = 0.008
Central Nervous System	Number (%) out of 11	2 (18.2%)	2 (18.2%)	3 (27.3%)	4 (36.4%)	p = 0.8
Other	Number (%) out of 16	1 (6.3%)	1 (6.3%)	6 (37.5%)	8 (50%)	p = 0.03
Multiple	Number (%) out of 5	0 (0.0%)	2 (40.0%)	0 (0.0%)	3 (60.0%)	p = 0.3
Not Identified at Initial Evaluation	Number (%) out of 241	89 (36.9%)	75 (31.1%)	45 (18.7%)	32 (13.3%)	p <0.0001
Clinical Parameters						
Temperature (Min)	Median, (Q1-Q3)	36.0 (35.2-36.4)	36.2 (35.6-36.6)	36.2 (35.5-36.7)	36.0 (35.4-36.7)	p = 0.2
Temperature (Max)	Median, (Q1-Q3)	37.2 (37.0-37.8)	37.3 (36.8-37.9)	37.3 (36.9-38.2)	37.8 (37.2-38.4)	p < 0.001
Lactate	Median, (Q1-Q3)	1.9 (1.3-3.3)	2.1 (1.6-3.3)	2.2 (1.5-3.3)	2.6 (1.6-4.1)	p = 0.7
WBC.Max	Median, (Q1-Q3)	13.5 (8.5-17.2)	12.2 (8.4-17.4)	13.9 (10.2-17.9)	14.6 (9.1-21.1)	p = 0.02
Procalcitonin	Median, (Q1, Q3)	0.3 (0.1-0.9)	0.3 (0.1-1.1)	0.6 (0.2-2.6)	5.6 (1.7-25.8)	p < 0.0001
SeptiScore	Median, (Q1-Q3)	4.3 (3.8-4.7)	5.6 (5.3-5.8)	6.8 (6.5-7.0)	8.7 (8.0-10.1)	p < 0.0001

* If small sample size (<5) in one or more categories, implying an increased uncertainty in the quantitative value of p, then calculation of p was performed by Monte Carlo simulation-based method [see https://www.statskingdom.com/310GoodnessChi.html for applet and R code].

** "Other culture/results" includes the following sample types: bronchial combicath, bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), pus, nares, stool, throat swab, drain fluid, body fluid, interstitial fluid, skin

*** including 7 blood culture false positives

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

FIGURE 5